Molecular subtypes identified by gene expression profiling in early stage endometrioid endometrial adenocarcinoma
Molecular subtypes identified by gene expression profiling in early stage endometrioid endometrial adenocarcinoma作者机构:Department of Obstetrics and Gynecology Peking UniversityPeople's Hospital Beijing 100044 China
出 版 物:《Chinese Medical Journal》 (中华医学杂志(英文版))
年 卷 期:2013年第126卷第19期
页 面:3680-3684页
核心收录:
学科分类:0710[理学-生物学] 1002[医学-临床医学] 07[理学] 08[工学] 09[农学] 071007[理学-遗传学] 0901[农学-作物学] 0836[工学-生物工程] 090102[农学-作物遗传育种]
主 题:endometrioid adenocarcinoma molecular classification gene expression profiling risk factor
摘 要:Background Early stage (FIGO stage Ⅰ-Ⅱ) endometrioid endometrial adenocarcinoma (EEA) is very common in clinical ***,patients with the early stage EEA show various clinical behaviors due to biological ***,we aimed to discover distinct classes of tumors based on gene expression profiling,and analyze whether the molecular classification correlated with the histopathological stages or other clinical *** Hierarchical clustering was performed for class discovery in 28 eady stage EEA samples using a special cDNA microarray chip containing 492 genes designed for endometrial *** between clinicopathologic parameters and our classification were *** the significance analysis of microarrays (SAM) array was used to identify the signature genes according to the tumor grade and myometrial *** Three tumor subtypes (subtypes Ⅰ,Ⅱ and Ⅲ) were identified by hierarchical clustering,each subtype had different clinicopathological factors,such as tumor grade,myometrial invasion status,and FIGO ***,SAM analysis showed 34 up-regulated genes in high grade tumors,and 38 up-regulated genes and 1 down-regulated in deep myometrial invasive *** overlap genes between these two high-risk factors were markedly up-regulated in subtype Ⅰ,but down-regulated in subtype Ⅲ.Conclusion We have identified novel molecular subtypes in early stage *** gene signatures characterize each tumor subtype,which could be used for recognizing the tumor risk and providing a basis for further treatment stratification.